	US 12,220,453 B2
	Compositions and treatments for Haemophilus influenzae
Terrence L. Stull, Phoenix, AZ (US); Daniel J. Morton, Oklahoma City, OK (US); Thomas W. Seale, Edmond, OK (US); and Paul W. Whitby, Chandler, AZ (US)
Assigned to The Board of Regents of the University of Oklahoma, Norman, OK (US)
Filed by The Board of Regents of the University of Oklahoma, Norman, OK (US)
Filed on Mar. 14, 2022, as Appl. No. 17/694,639.
Application 17/694,639 is a continuation of application No. 15/580,060, granted, now 11,305,002, previously published as PCT/US2016/036180, filed on Jun. 7, 2016.
Claims priority of provisional application 62/208,023, filed on Aug. 21, 2015.
Claims priority of provisional application 62/173,205, filed on Jun. 9, 2015.
Prior Publication US 2022/0202924 A1, Jun. 30, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/102 (2006.01); A61K 9/00 (2006.01); C07K 14/285 (2006.01)

CPC A61K 39/102 (2013.01) [A61K 9/0019 (2013.01); C07K 14/285 (2013.01); C07K 2317/32 (2013.01); C07K 2317/34 (2013.01)]

20 Claims

1. A peptide composition, comprising a plurality of peptides comprising at least three different amino acid sequences, wherein each of the at least three different amino acid sequences is from an externally exposed loop of an outer membrane protein (OMP) selected from the group consisting of:

SEQ ID NO: 97, SEQ ID NO: 101, SEQ ID NO: 589, SEQ ID NO: 462, SEQ ID NO: 590, SEQ ID NO: 308, SEQ ID NO: 123, SEQ ID NO: 139, SEQ ID NO: 245, SEQ ID NO: 460, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 153, SEQ ID NO: 321, SEQ ID NO: 325, SEQ ID NO: 145, SEQ ID NO: 350, SEQ ID NO: 268, SEQ ID NO: 341, and SEQ ID NO: 517;

each of the peptides induces an antibody response against a Nontypeable Haemophilus influenzae (NTHi); and

each of the peptides is linked together to form a fusion polypeptide.